FR | EN CONTACT NEWS & EVENTS INVESTORS OUR SCIENCE ABOUT US HOME Management Appearing left to right: Sébastien Bolze | Pascale Fouqueray | Noah D. Beerman | Pascale Malgouyres | Thomas Kuhn | Sophie Bozec | Eric Massou Thomas Kuhn, Pharm D, MBA Chief Executive Officer, co-founder Thomas joined Merck KGaA in 2000, where he held various positions in clinical development, largely in the area of diabetes. Between 2004 and 2007 he directed global R&D projects, with two products in Phase 2 clinical trials, and life cycle management projects, specifically for Glucophage®, the current reference in diabetes treatment. After the integration of Serono in 2007, Thomas was involved in refining Merck Serono's strategy. With the decision to divest from diabetes as an integrated therapeutic area, Thomas drove the project to relocate the diabetes assets, leading to the establishment of Poxel. Thomas received a pharmacy degree from the University of Lyon I (France) and an MBA from Ashridge University (UK). Noah D. Beerman, MBA Executive Vice President, Business Development and President, US Operations Noah has been an executive in the biopharmaceutical industry for more than 25 years, beginning at Repligen, Sandoz, Curis, and Technology Management & Funding. He then joined Indevus Pharmaceuticals, where he was responsible for multiple licensing, co-promotion and M&A agreements, establishing an industry-leading profile in corporate development as Chief Business Officer for the company. Subsequently, Noah was President, CEO, and Director of RXI Pharmaceuticals (now Galena BioPharma), and until 2013 Executive Vice President and Chief Operating Officer at Coronado Biosciences. Most recently he has served as an executive consultant in the biopharmaceutical industry, and Director on the Board of Trasir Therapeutics. Noah holds an MBA from Northeastern University’s High Technology Program and a Bachelors of Science in molecular genetics from the University of Rochester. Sébastien Bolze, Pharm D, PhD Executive Vice President, Non Clinical Development, co-founder Sébastien has broad experience in drug development from discovery screening to first-in-man clinical trials. He was global head of the preclinical candidate selection unit at Solvay Pharmaceuticals, a multidisciplinary unit providing support to research projects from optimization of validated hits to delivery of candidates for preclinical development. From 2003 to 2006, Sébastien was executive head of the ADME department at Fournier Pharma. He acquired strong organizational and managerial experience in research projects within a multidisciplinary and global environment. Sébastien has also co-authored numerous research publications and posters. Sébastien is a pharmacist and holds a PhD in pharmacokinetics and drug metabolism from the University of Lyon I (France). Sophie Bozec, PhD Senior Vice President, R&D Pharmacology, co-founder Sophie joined Merck KGaA in 1998 where she managed a drug discovery team in a pharmacology department. She has acquired a strong experience for managing research projects from target identification to preclinical development candidates. Sophie has developed her knowledge in models (in vivo and in vitro) used in research programs for identifying preclinical development candidates in the diabetes field. She acquired a solid expertise in metabolic diseases particularly in the diabetes field. This experience in pharmacology led Sophie to support a clinical development compound for all preclinical pharmacology aspects. Sophie received a PhD in nutrition, metabolism and obesity from the Paris VII University. Pascale Fouqueray, MD, PhD Executive Vice President, Clinical Development, co-founder Pascale joined Merck KGaA in 2000 from Paris VII University, where she was Assistant Professor of physiology. At Merck KGaA, her activities were centered on metabolism, with a particular focus on diabetes and obesity but also including lipids and uric acid metabolism. She was responsible for the clinical development of compounds for the treatment of diabetes and gout disease, working on strategies to define and reach proof-of- concept and investigate mechanisms of action. Pascale graduated from medical school at the University of Angers (France) and then specialized in endocrinology and metabolism at the University of Paris V. She received a PhD from the University of Paris XI. Pascale Malgouyres, Pharm D, MSc Executive Vice President, Commercial Development, co-founder Pascale started her career at the French affiliate of Eli Lilly as a clinical research associate, subsequently moving to the sales department. She then joined Procter & Gamble Pharmaceuticals, where she was responsible for marketing programs in rheumatology. Pascale joined Merck KGaA in 1992, where she held various positions in national and international marketing departments. She has focused on diabetes since 2001 as a marketing contributor to the global product teams in charge of three different new chemical entities (NCEs) in development. In this capacity, she developed a comprehensive approach to channel marketing input towards research, and she developed methods to produce business cases. Her last position at Merck Serono was global marketing director of the Glucophage® franchise. Pascale received a pharmacy degree from the University of Lyon I (France) as well as an MSc in clinical pharmacokinetics. Eric Massou, Master of Finance, Certified Public Accountant Chief Financial Officer Eric has 16 years' experience as an external auditor at Mazars and Ernst & Young, where he was mainly in charge of industrial groups such as Becton Dickinson, Black & Decker, Brenntag and Candia. Eric acquired experience as a financial controller and group CFO at Veriplast Packaging, a plastic packaging company operating in seven European countries. There, he was involved in all recurrent financial aspects and monitored two major vendor due diligence projects to welcome Charterhouse in 2004 and SUN in 2007 as new shareholders. In addition, Eric was on the deal team for all M&A activities and in charge of external stakeholders, and he raised all necessary new monies to support business growth and finance new industrial capital expenditures. Eric received a Master of Finance at the BESS program of Trinity College Dublin (Ireland) as well as the French CPA. © Poxel SA 2016 Legal Disclaimer | Site Map Home About Us Our Science Investors News & Events Contact